CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
OPERATING EXPENSES
General and administrative	$ 102	$ 157	$ 215	$ 382
Research and development	112	220	379	377
Total operating expenses	214	377	594	759
Interest and other expense, net	(6)	25	9	36
Loss from operations before taxes	208	402	603	795
Income tax benefit	(2)	(12)	(10)	(26)
NET LOSS	206	390	593	769
Less: Net Loss attributable to the noncontrolling interest	0	0	0	0
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 206	$ 390	$ 593	$ 769
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutic Corp. stockholders (in dollars per share)	$ 0.01	$ 0.01	$ 0.01	$ 0.02
Basic and diluted shares outstanding (in shares)	40,885	40,885	40,885	40,885